CN Patent

CN117398346A — 用于口服给药的依达拉奉混悬剂

Assigned to Tanabe Pharma Corp · Expires 2024-01-16 · 2y expired

What this patent protects

本申请涉及用于人类口服给药的依达拉奉混悬剂，其包含依达拉奉颗粒、分散剂、增稠剂和水；其中所述增稠剂是选自黄原胶和黄芪胶粉中的一种或两种。

USPTO Abstract

本申请涉及用于人类口服给药的依达拉奉混悬剂，其包含依达拉奉颗粒、分散剂、增稠剂和水；其中所述增稠剂是选自黄原胶和黄芪胶粉中的一种或两种。

Drugs covered by this patent

Patent Metadata

Patent number
CN117398346A
Jurisdiction
CN
Classification
—
Expires
2024-01-16
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.